Top Story

Neogap Therapeutics move into clinic with personalized cancer immunotherapy

Neogap Therapeutics move into clinic with personalized cancer immunotherapy

21-Jan-2025

|

By Helen Albert

Editor's Choice

FDA approves first mesenchymal stromal cell therapy

FDA approves first mesenchymal stromal cell therapy

19-Dec-2024

|

By Clara Rodriguez Fernandez

Headlines

Nanobiotix’s radiotherapy-activated nanoparticle cancer candidate...

Biosimilars in the UK: Insights from Biocon Biologics

Umoja raises $100 million to boost its CAR-T cell gene therapy pipeline

Hinge Bio raises $30 million to progress B cell lupus therapy

Windward Bio launches to develop potential best-in-class antibody...

Alchemab and Lilly collaborate to discover and develop ALS therapies

→

In focus

Aditum Bio and Leads Biolabs join forces in new company to fight autoimmune diseases

07-Nov-2024 By Larissa Warneck-Silvestrin

Is GMP grade good enough? What mRNA manufacturers need to know when buying raw materials

Paid for and in partnership with Thermo Fisher Scientific - Biosciences

Abzena announces major expansion of its biologics manufacturing facility

31-Oct-2024 By Larissa Warneck-Silvestrin

Eliminating Variables Is Central to Kitting Design

Paid for and content provided by Yourway

Featured

Insight

Top 10 rare disease pharma sees 10.4% rise in therapy start

By Liza Laws

Top 10 rare disease pharma sees 10.4% rise in therapy start

Bio developments

→

Neogap Therapeutics move into clinic with personalized cancer immunotherapy

Neogap Therapeutics move into clinic with personalized cancer immunotherapy

21-Jan-2025

By Helen Albert

Nanobiotix’s radiotherapy-activated nanoparticle cancer candidate enters Phase 2

Nanobiotix’s radiotherapy-activated nanoparticle cancer candidate enters Phase 2

21-Jan-2025

By Larissa Warneck-Silvestrin

Biosimilars in the UK: Insights from Biocon Biologics

Biosimilars in the UK: Insights from Biocon Biologics

21-Jan-2025

Partner insightMore →

Internal Standard (IS) Variation Case Studies: Emerging from Three Common IS Challenges

Content provided by WuXi AppTec

ICH M10 Guidance: Harmonization and Modification to Bioanalytical Method Variation

Content provided by WuXi AppTec

Difco TC Yeastolate UF in scale-up optimization

Content provided by Thermo Fisher Scientific Gibco Culture for Bioprocessing

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences

Markets & regulation

→

Biosimilars in the UK: Insights from Biocon Biologics

Biosimilars in the UK: Insights from Biocon Biologics

21-Jan-2025

FDA approves first mesenchymal stromal cell therapy

FDA approves first mesenchymal stromal cell therapy

19-Dec-2024

By Clara Rodriguez Fernandez

Cell and gene therapy access model launches in US

Cell and gene therapy access model launches in US

05-Dec-2024

By Helen Albert

BridgeBio wins FDA approval for inherited cardiomyopathy treatment

BridgeBio wins FDA approval for inherited cardiomyopathy treatment

26-Nov-2024

By Helen Albert

Contract manufacturing & logistics

→

Eli Lilly invests $3bn in injectable drug manufacturing facility

Eli Lilly invests $3bn in injectable drug manufacturing facility

10-Dec-2024

By Clara Rodriguez Fernandez

Adragos Pharma snaps up Baccinex to expand CDMO network

Adragos Pharma snaps up Baccinex to expand CDMO network

26-Nov-2024

Abzena’s advanced drug development showcased at CPHI Milan

Abzena’s advanced drug development showcased at CPHI Milan

01-Nov-2024

By Liza Laws

CRO NovAliX teams with Bruker to advance drug development

CRO NovAliX teams with Bruker to advance drug development

29-Oct-2024

By Liza Laws

Expand your knowledge

Industry Newsletters

Choose from regular, topic-based and special edition briefings

Resource centre

Discover cutting edge insight from our partners

Events & webinars

Explore our programme of live & on-demand content